Introduction
The incidence of inflammatory bowel disease [IBD] in Western Europe has remained relatively stable over recent years, but is increasing in developing countries. 1 It is known that genetic and environmental factors play an important role in the aetiology of IBD. Over recent years, there has been tremendous progress in unravelling the genetic background of IBD, and 200 regions on the human genome have been found to be associated with IBD. 2 Still, the genetic architecture only partly explains the susceptibility to IBD, suggesting that environmental factors contribute to the development of Crohn's disease [CD] and ulcerative colitis [UC] . 3 The increasing prevalence of IBD among individuals migrating from low-prevalence regions to high-prevalence regions suggests a role for environmental factors, such as a Westernised diet or lifestyle. [4] [5] [6] Data on ethnic differences regarding phenotypic manifestations of IBD are not consistent, and most published studies so far have relatively small sample sizes. [7] [8] [9] [10] [11] Since the number of non-Caucasians [patients from non-European descent] with IBD is increasing in Western European countries, 12 potential phenotypic differences between Caucasian and non-Caucasian IBD patients are of increasing relevance. Treatment paradigms are based on studies predominantly conducted in the Caucasian IBD population, 13 and therefore recognition of ethnic differences in phenotypic manifestations will aid clinical decision making such as optimising individual management and tailoring treatment options. The aim of this study is therefore 2-fold: 1] to gain more insight into the phenotypic differences between Caucasian and non-Caucasian IBD patients in The Netherlands; and 2] to explore the influence of country of birth on the clinical phenotype in non-Caucasian IBD patients by comparing non-Caucasians born in Europe with non-Caucasians born in nonEuropean countries.
Methods

Study design and study population
We conducted a multicentre analysis of IBD patients enrolled in the Dutch IBD Biobank, which is part of the Parelsnoer Institute [www. parelsnoer.org]. Since 2007, every IBD patient treated in any one of the eight University Medical Centers [UMCs] is asked to participate in the Dutch IBD Biobank. The Dutch IBD Biobank collects clinical data through an information model that contains 225 IBD-related items. The IBD-related items used for this paper and their definitions can be found in Supplementary File 1, available as Supplementary data at ECCO-JCC online. These items are retrieved from medical records and are stored in a central database that can be accessed via web-based trough as a secure transfer. IBD patients are continuously being enrolled in the Dutch IBD Biobank, and data are collected prospectively.
14 At the moment of data freeze [17 July 2014] , the Dutch IBD Biobank contained 3388 IBD patients. For this study, patients were excluded if information on ethnicity was missing. Caucasian IBD patients from West or Central European descent were excluded when they were not born in The Netherlands or when their parents were not born in The Netherlands or Europe.
Cohort
The clinician addressed ethnicity/descent during consultation; patients were asked about their descent, country of birth, and country of birth of their parents.
To address the influence of ethnic differences on disease behaviour, IBD patients were divided in two broad groups according to their ethnicity [ Figure 1 second group consists of a heterogeneous group of ethnicities, for the current comparative analysis we will refer to this specific group as "non-CEU".
To address the influence of country of birth on phenotypic manifestations of IBD, the second group was then subdivided in two broad groups according to country of birth [ Figure 1 ]:
• 
Statistical analysis
In all analyses, UC patients also included IBD-unclassified [IBD-U] and IBD-indeterminate [IBD-I] patients. Quantitative variables between the different groups were compared using the Mann-Whitney U test.
Non-European descent (non-CEU) n=233
European descent (CEU) n=2,921
Born in Europe n=117
Born in nonEuropean country n=115 No difference was found in disease localisation in UC between CEU patients and non-CEU patients [ Table 2 ].
Medication use in CEU and non-CEU IBD patients
The use of anti-TNF-alpha agents was more frequent in non-CEU IBD patients than in CEU IBD patients [45% vs 38%, p = 0.042]. The use of anti-TNF-alpha agents was more frequent in non-CEU patients with UC compared with CEU patients with UC [28% vs 19%, p = 0.047]. Immunomodulators were more often used in non-CEU IBD patients than in CEU IBD patients [77% vs 66%, p = 0.001]. Supplementary File 4, Table 1 shows no statistically significant differences in the use of anti-TNF-alpha agents or the use of immunomodulators in a subanalysis between the three largest non-CEU groups [African, Hindustani, Turkish]. The use of azathioprine and 6-thioguanine was higher among non-CEU IBD patients than CEU IBD patients [58% vs 49%, p = 0.010] and [7% vs 3%, p = 0.010], respectively. This higher use of azathioprine and 6-thioguanine was predominantly found in non-CEU patients with UC compared with CEU patients with UC [57% vs 41%, p = 0.003] and [11% vs 4%, p = 0.001], respectively [ Table 3 ].
Surgery rates in CEU and non-CEU IBD patients
There was no statistically significant difference in overall surgery rates and the number of stoma and pouches between CEU patients and non-CEU patients [Supplementary File 4, Table 2 ].
At 2 years after IBD diagnosis, the proportion of IBD patients who remained free of IBD surgery was 84% (95% confidence interval [CI]: 83%-86%) in CEU patients and 91% [95% CI: 86%-94%] in non-CEU patients [ Figure 2 ]. At 5 years after IBD diagnosis, the proportion of IBD patients who remained free of surgery was 74% [95% CI: 72%-76%] in CEU patients and 75% [95% CI: 
Extra-intestinal manifestations in CEU and non-CEU IBD patients
There were no statistically significant differences in the prevalence of skin manifestations, musculoskeletal manifestations, ocular manifestations, osteopenia, or thromboembolic events between CEU patients and non-CEU patients [Supplementary File 4, 
Phenotypic differences between non-CEU IBD patients born in Europe and non-CEU IBD patients born in non-European countries who migrated to The Netherlands
Demographic differences between non-CEU IBD patients born in Europe and non-CEU IBD patients born in nonEuropean countries
There were no differences in IBD diagnosis or sex-ratio between non-CEU patients born in Europe and non-CEU patients born in non-European countries. Non-CEU patients born in Europe were younger at time of inclusion than non-CEU patients born in nonEuropean countries [32.0 vs 43.1 years, p < 0.001]. The median disease duration at inclusion was longer in non-CEU patients born in non-European countries compared with European countries [11.7 vs 8.0 years, p = 0.006] [ Table 4 ].
Age at diagnosis in non-CEU IBD patients born in Europe and non-CEU IBD patients born in non-European countries
Non-CEU IBD patients born in Europe were diagnosed at a lower age than non-CEU IBD patients born in non-European countries who migrated to The Netherlands [22.7 vs 28.9 years old, p < 0.001] [ Table 4 ].
Disease behaviour in non-CEU IBD patients born in Europe and non-CEU IBD patients born in non-European countries
Non-CEU patients born in Europe were diagnosed with IBD before the age of 17 years more often compared with non-CEU patients born in non-European countries [29% vs 9%, p = 0.002]. Non-CEU patients born in non-European countries were more often diagnosed with IBD after the age of 40 years [22% vs 7%, p = 0.008]. According to the Montreal classification, division of disease location [L] in CD did not differ between non-CEU patients born in Europe and non-CEU patients born in non-European countries. No difference was found in disease localisation in UC between non-CEU patients born in Europe and non-CEU patients born in non-European countries [ Table 5 ].
Medication use in non-CEU IBD patients born in Europe and non-CEU IBD patients born in non-European countries
There were no differences in medication use between non-CEU IBD patients born in Europe and non-CEU IBD patients born in nonEuropean countries. Except for the use of mercaptopurine, which was higher among non-CEU patients with UC born in non-European countries than non-CEU patients with UC born in European countries [30% vs 10%, p = 0.015] [ Table 6 ].
Surgery rates in non-CEU IBD patients born in Europe and non-CEU IBD patients born in non-European countries
There was no statistically significant difference in overall surgery rates and the numbers of stoma and pouches between non-CEU IBD a Missing values were scored as non-present. *p < 0.01; **p < 0.001. NL, Netherlands; EU, Europe; CEU, Central European descent; CD, Crohn's disease. GI, gastro-intestinal. a These percentages are calculated for 57 non-CEU patients born in NL/EU and 53 non-CEU patients born in non-European countries with CD. Table 5 ].
Extra-intestinal manifestations in non-CEU IBD patients born in Europe and non-CEU IBD patients born in nonEuropean countries
There were no statistically significant differences in the prevalence of skin manifestations, musculoskeletal manifestations, ocular manifestations, osteopenia, or thromboembolic events between non-CEU IBD patients born in Europe and non-CEU IBD patients born in a non-European country [Supplementary File 4, Table 6 ].
Discussion
In this large prospective cohort study, we aimed to explore the impact of ethnicity and country of birth on phenotype in IBD patients. We observed that non-CEU patients have more upper GI disease, more stricturing disease and use anti-TNF agents and immunomodulators more often than CEU patients. Furthermore, we found that non-CEU IBD patients born in Europe were diagnosed at a lower age than non-CEU IBD patients born in non-European countries who migrated to The Netherlands.
Worse disease behaviour in non-CEU compared with CEU IBD patients
We found upper GI disease and anal stenosis to be more common in non-CEU patients compared with CEU patients with CD after a median disease duration of 10 years. Most studies reporting on progression of CD behaviour are conducted in Western populations. 16, 17 One study compared disease behaviour between Asian and Australian patients with CD and found stricturing disease to be more common in Asians with CD at diagnosis. Furthermore, they reported a cumulative probability of 20% that CD behaviour would change from inflammatory to stricturing or penetrating disease independent of ethnicity. 9 A review from the UK showed a more severe disease in Asian migrants compared with Caucasian non-migrants. 18 In our cohort, we had six CD patients from Asian descent; one of them had an anal stenosis. However, we were not able to conduct a statistical analysis due to the small sample size. On the other hand, a large review stated that there seems to be no difference in complicated disease behaviour among IBD patients from African American, Asian, and Hispanic descent living in the USA. 19 Interestingly, a study from Belgium compared Moroccan migrants with Caucasian migrants, the latter being a diverse group of Eastern European and Middle Eastern migrants, and found a more severe disease behaviour [more penetrating disease and anti-TNF use] among Moroccan migrants. 20 It has been suggested that a more severe disease behaviour among non-Caucasians is a consequence of delayed disease presentation. However, in our study we could not detect differences in disease behaviour between non-CEU IBD patients born in Europe or non-CEU IBD patients born in non-European countries. A more severe disease behaviour due to a delayed disease presentation is therefore unlikely. To date, genetic risk variants explain only about 10% of the disease risk, which suggests that environmental factors play an important role in the disease pathogenesis. A study from England has shown that disease localisation follows the pattern of the indigenous population after one generation, 21 but other articles challenge these findings. 22 As environmental risk factors play an important role in IBD, a severe disease phenotype could therefore concur with the duration of exposure to these risk factors.
Higher use of IBD medication in non-CEU compared with CEU IBD patients
We found non-CEU IBD patients to use anti-TNF agents and immunomodulators more frequently than CEU patients. In previous studies, the use of medical therapy was similar in Asians compared with Australians. 9, 23 Higher anti-TNF-alpha use in our cohort could be explained by the more severe disease behaviour [ie more stricturing disease] in non-CEU patients with CD in our cohort. Indeed, a previous study found no differences in infliximab use between African Americans and Caucasian CD patients by only selecting patients with penetrating Crohn's disease. 24 There were no major differences in extra-intestinal manifestations [EIMs] or surgery rates, the latter previously being attributed to differences in health insurance status. 19 However, as inhabitants of The Netherlands all have mandatory health insurance, this possible explanation does not suffice for our cohort. In line with our results no differences in colectomy rates were found between Asians and Caucasians, but interestingly a subgroup analysis across ethnic groups between Indian, Pakistani, Bangladeshi [Asians] , and Caucasians did show significant differences in colectomy rates. 25   Table 6 . Medication use in non-CEU IBD patients born in Europe and non-CEU IBD patients born in non-European countries.
4.3. Difference in age of onset IBD between non-CEU IBD patients born in Europe compared with non-CEU IBD patients born in non-European countries Changes in lifestyle, such as a Westernised diet, have been implicated to play a role in the aetiology of IBD. [4] [5] [6] In our cohort, we were able to assess the effect of exposure to a Western lifestyle. We found that IBD patients with non-CEU descent born in Europe were diagnosed with IBD at a lower age. This important finding made us speculate that a Western lifestyle might trigger IBD onset more early in life in a genetic susceptible patient; however we were not able to deduce a causal relationship. We realise that the patients in our non-CEU IBD population are genetically very heterogeneous; with most patients having mixed descent [n = 72], being African [n = 37], or Hindustani [n = 37]. On the other hand, the non-CEU IBD patients born in nonEuropean countries all have been exposed to a non-Western lifestyle before migrating to The Netherlands. We were not able to address at what age the patient migrated to The Netherlands or whether the diagnosis of IBD was diagnosed in The Netherlands or country of birth. Although phenotype differences were studied in a large cohort with a total of 2921 CEU IBD patients, we had a relatively lower total number of 233 non-CEU IBD patients. It was therefore not possible to conduct a statistical analysis with enough power to detect differences associated with a particular non-CEU population or in a particular non-European country. Still, IBD research in other ethnicities than patients with an European ancestry is of utmost importance and is currently almost non-existent [except for Asia]. 26 It has been established that socioeconomic status is associated with IBD risk. 27, 28 Unfortunately, we had no data on the socioeconomic status at our disposal.
In conclusion, this study shows that both ethnicity and country of birth are associated with different phenotypes in IBD patients. Furthermore, we found that non-CEU IBD patients born in Europe, exposed to a Westernised lifestyle, have an earlier age of onset compared with non-CEU IBD patients born outside Europe. In clinical practice, clinicians should be aware of distinct phenotype characteristics in the non-CEU IBD populations. 
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